Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)
276
Zitationen
6
Autoren
1992
Jahr
Abstract
Radiolabelled meta-iodobenzylguanidine (MIBG) is widely used in the diagnosis, follow-up and treatment of patients with tumours of neural crest origin. Some commonly prescribed and readily available over-the-counter medicines interfere with the uptake and biodistribution of this radiopharmaceutical. This may lead to poor concentration of radiolabelled MIBG within the target organs and tissues. The clinical implications are a potentially inaccurate assessment of tumour burden during diagnostic studies and a suboptimal radiation dose when MIBG is employed for targetted radiotherapy. In order to avoid false negative results a comprehensive list of prescribed and over-the-counter medicines that have the potential to inhibit uptake of MIBG has been compiled. It is hoped that this will help nuclear medicine physicians to avoid this pitfall.
Ähnliche Arbeiten
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.421 Zit.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.816 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.915 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.094 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.408 Zit.